Hailey Borg
Healthcare: Biotech and Pharma Innovation
Expected Outperformers: Moderna, Vertex Pharmaceuticals, BioNTech
Why: Expanding mRNA applications in cancer and personalised medicine. Vertex is a leader in cystic fibrosis treatments with a promising gene-editing pipeline.
Wildcard: CRISPR Therapeutics
Why: Gene therapy approvals could catalyse exponential growth for this early-stage biotech company.
Financial Services: The DeFi and Payment Revolution
Expected Outperformers: Visa, Mastercard, PayPal
Why: Expansion into digital currencies and a robust consumer spending recovery.
Wildcard: Block (formerly Square)
Why: Its blockchain payment solutions and small business services offer strong growth potential.
Industrial Automation and Robotics
Expected Outperformers: ABB, Fanuc Corporation, Rockwell Automation
Why: Labour shortages and rising costs will drive demand for automation in manufacturing and logistics.
Wildcard: UiPath
Why: Its market position in robotic process automation (RPA) for enterprise clients ensures significant growth opportunities.
By identifying these outperformers and risks, investors can better navigate 2025’s complexities and capitalise on emerging opportunities. Let me know if you’d like a deep dive into any specific company or sector!
You Might Also Like
Latest Article
CrediaBank Profit Surges As Bank Prepares For HSBC Malta Takeover
CrediaBank has reported strong financial results for 2025, marking a year of record growth as the Greek lender prepares to acquire a controlling stake in HSBC Bank Malta. CrediaBank is set to acquire 70.03% of HSBC Malta, subject to regulatory approvals, with the transaction expected to be completed by the first quarter of 2027. The … Continued
|
6 March 2026
Written by MeetInc.
NYSE Owner Backs MFSA-Licensed Crypto Exchange In $25bn Deal
|
5 March 2026
Written by MeetInc.
SME Chamber And SHE Hub Launch ‘Give To Gain’ Business Forum
|
4 March 2026
Written by MeetInc.
